Prognostic significance of CD44, platelet-derived growth factor receptor α, and cyclooxygenase 2 expression in renal cell carcinoma

Archives of Pathology and Laboratory Medicine

Volumn 131, Issue 2, 2007, Pages 261-267

  Tawfik, Ossama W ^a   Kramer, Brandan ^a   Shideler, Barbara ^a   Danley, Marsha ^a   Kimler, Bruce F ^a   Holzbeierlein, Jeffrey ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; HERMES ANTIGEN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR;

ADULT; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL TYPE; DISEASE FREE SURVIVAL; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD44; CARCINOMA, RENAL CELL; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PLATELET-DERIVED GROWTH FACTOR; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33846994351     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Murphy WM, Grignon DJ, Perlman EJ. Kidney tumors in adults. In: Tumors of the Kidney, Bladder and Related Urinary Structures. Washington, DC: Armed Forces Institute of Pathology; 2004;101-240. Atlas of Tumor Pathology, 4th series, fascicle 1.
2. Skinner DG, Colvin RB, Vermillion CD, et al. Diagnosis and management of renal cell carcinoma: a clinical and pathologic study of 309 cases. Cancer. 1971;28:1165-1177.
3. Medeiros LJ, Gelb AB, Weiss LM. Renal cell carcinoma: prognostic significance of morphologic parameters in 121 cases. Cancer. 1988;61:1639-1651.
4. Rioux-Leclercq N, Turlin B, Bansard J, et al. Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma. Urology. 2000;55:501-505.
5. Cheville J, Zincke H, Lohse C, et al. pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival. Cancer. 2002;94:2180-2184.
6. Abou-Rebyeh H, Borgmann V, Nagel R, et al. DNA ploidy is a valuable predictor for prognosis of patients with resected renal cell carcinoma. Cancer. 2001;92:2280-2285.
7. Ljungberg B, Bozoky B, Kovacs G, et al. p53 expression in correlation to clinical outcome in patients with renal cell carcinoma. Scand J Urol Nephrol. 2001;35:15-20.
8. Di Silverio F, Casale P, Colella D, et al. Independent value of tumor size and DNA ploidy for the prediction of disease progression in patients with organ-confined renal cell carcinoma. Cancer. 2000;88:835-843.
9. Cotran RS, Kumar V, Collins T, Robbins SL. Pathologic Basis of Disease. 6th ed. Philadelphia, Pa: WB Saunders; 1999:70-71, 279-281, 305, 991-994.
10. Sulzbacher I, Birner P, Traxler M, et al. Expression of platelet-derived growth factor-αα receptor is associated with tumor progression in clear cell renal cell carcinoma. Am J Clin Pathol. 2003;120:107-112.
11. Gilcrease M, Guzman-Paz M, Niehans G, et al. Correlation of CD44S expression in renal clear cell carcinomas with subsequent tumor progression or recurrence. Cancer. 1999;86:2320-2326.
12. Fischer C, Georg CH, Kraus S, et al. CD44s, E-Cadherin and PCNA äs markers for progression in renal cell carcinoma. Anticancer Res. 1999;19:1513-1518.
13. Rioux-Leclercq N, Epstein J, Bansard J, et al. Clinical significance of cell proliferation, microvessel density, and CD44 adhesion molecule expression in renal cell carcinoma. Hum Pathol. 2001;32:1209-1215.
14. Yildiz E, Gokce G, Kilicarslan H, et al. Prognostic value of the expression of Ki-67, CD44 and vascular endothelial growth factor, and microvessel invasion, in renal cell carcinoma. BJU Int. 2004;93:1087-1093.
15. Li N, Tsuji M, Kanda K, et al. Analysis of CD44 isoform V10 expression and its prognostic value in renal cell carcinoma. BJU Int. 2000;85:514-518.
16. Heider K, Ratschek M, Zatloukal K, et al. Expression of CD44 isoforms in human renal cell carcinomas. Virchows Arch. 1996;428:267-273.
17. Thrasher J. Molecular markers in renal cell carcinoma not quite ready for prime time. Cancer. 1999;86:2195-2197.
18. Bamias A, Chorti M, Deliveliotis C, et al. Prognostic significance of CA125, CD44, and epithelial membrane antigen in renal cell carcinoma. Urology. 2003;62:368-373.
19. Paradis V, Ferlicot S, Ghannam E, et al. CD44 is an independent prognostic factor in conventional renal cell carcinomas. J Urol. 1999;161:1984-1987.
20. Chen Q, Shinohara N, Abe T, et al. Significance of COX-2 expression in human renal cell carcinoma cell lines. Int J Cancer. 2004;108:825-832.
21. Kokawa A, Kondo H, Gotoda T, et al. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer. 2001;91:333-338.
22. Shirahama T, Arima J, Akiba S, et al. Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer. 2001;92:188-193.
23. Miyata Y, Koga S, Kanda S, et al. Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. Clin Cancer Res. 2003;9:1741-1749.
24. Hashimoto Y, Kondo Y, Kimura G, et al. Cyclooxygenase-2 expression and relationship to tumour progression in human renal cell carcinoma. Histopathology. 2004;44:353-359.
25. Grizzle WE, Myers RB, Arnold MM, et al. Evaluation of biomarkers in breast and prostate cancer. J Cell Biochem. 1992;19:259-266.